Chen-Pin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chen-Pin Wang has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Mary Jo Pugh
Informatics Decision-Enhancement, and Analytic Sciences (IDEAS) Center of Innovation, VA Salt Lake City Health Care System , Salt Lake City, UT 84148
6 shared publications - Amelie G. Ramirez
Department of Population Health Sciences, Institute for Health Promotion Research, Long School of Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio , San Antonio, TX
4 shared publications Carlos Lorenzo
Department of Medicine, University of Texas Health Science Center at San Antonio
3 shared publicationsJohn R. Downs
3 shared publicationsMegan Amuan
3 shared publicationsSteven Weitman
3 shared publications
Latest Publications
- 21 July 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 104
Regional and statewide hysterectomy-corrected endometrial cancer incidence and five-year relative survival in Texas
- 21 July 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 104
Regional and statewide hysterectomy-corrected endometrial cancer incidence and five-year relative survival in Texas
- Open Access
- 30 April 2026
- Published by Elsevier in SSRN Electronic Journal
Regional and Statewide Hysterectomy-Corrected Endometrial Cancer Incidence and Five-Year Relative Survival in Texas
Background: Rising endometrial cancer (EC) incidence nationwide, particularly among Hispanic women, and high prevalence of risk factors such as obesity and comorbidities in Texas, motivated us to estimate EC incidence rates (IRs) and survival by age (<50 year early-onset, ≥50 year late-onset), race-ethnicity (Non-Hispanic-White [NHW], -Black [NHB], Hispanic), histology (endometrioid, non-endometrioid), and area-based socioeconomic (SES) factors across Texas Health Service Regions (HSRs).Study Design: Between 2000-2019, a total of 42,571 women (20-79 years) with EC were reported from Texas within the Surveillance, Epidemiology, and End Results Program. IRs and 5-year relative survival were calculated using SEER*Stat. IRs were corrected for hysterectomy using Behavioral Risk Factor Surveillance System data.Results: Statewide EC IRs rose from 38.8 (2000-2009) to 44.5 (2010-2019), with the highest increase in the Upper-South (42.6 to 53.8). Across HSRs, Upper-South consistently had higher IRs among women <50 (13.9) and ≥50 years (112.7). Among those <50 years, Hispanics had the highest IRs (12.4), predominantly endometrioid tumors, whereas in women ≥50 years, NHB had the highest IRs (119.2) with a large proportion of non-endometrioid tumors. IRs were higher in areas with lower poverty, and higher education, income, and urbanization. Associations with unemployment were mixed. Worse survival outcomes were observed among NHBs, non-endometrioid, advanced-stage, and lower SES. Central Texas had more favorable survival outcomes compared to other HSR.Conclusion: EC IRs and survival rates in Texas largely mirror national trends, with regional differences likely reflecting sociodemographic and histologic distributions.
- 30 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRegional and Statewide Hysterectomy-Corrected Endometrial Cancer Incidence and Five-Year Relative Survival in Texas
Background: Rising endometrial cancer (EC) incidence nationwide, particularly among Hispanic women, and high prevalence of risk factors such as obesity and comorbidities in Texas, motivated us to estimate EC incidence rates (IRs) and survival by age (<50 year early-onset, ≥50 year late-onset), race-ethnicity (Non-Hispanic-White [NHW], -Black [NHB], Hispanic), histology (endometrioid, non-endometrioid), and area-based socioeconomic (SES) factors across Texas Health Service Regions (HSRs).Study Design: Between 2000-2019, a total of 42,571 women (20-79 years) with EC were reported from Texas within the Surveillance, Epidemiology, and End Results Program. IRs and 5-year relative survival were calculated using SEER*Stat. IRs were corrected for hysterectomy using Behavioral Risk Factor Surveillance System data.Results: Statewide EC IRs rose from 38.8 (2000-2009) to 44.5 (2010-2019), with the highest increase in the Upper-South (42.6 to 53.8). Across HSRs, Upper-South consistently had higher IRs among women <50 (13.9) and ≥50 years (112.7). Among those <50 years, Hispanics had the highest IRs (12.4), predominantly endometrioid tumors, whereas in women ≥50 years, NHB had the highest IRs (119.2) with a large proportion of non-endometrioid tumors. IRs were higher in areas with lower poverty, and higher education, income, and urbanization. Associations with unemployment were mixed. Worse survival outcomes were observed among NHBs, non-endometrioid, advanced-stage, and lower SES. Central Texas had more favorable survival outcomes compared to other HSR.Conclusion: EC IRs and survival rates in Texas largely mirror national trends, with regional differences likely reflecting sociodemographic and histologic distributions.
- Open Access
Impact of mid-life cardiovascular health on cognitive change in a bi-ethnic cohort
INTRODUCTION: Vascular risk factors contribute to cognitive decline and dementia; however, research across populations remains scarce. METHODS: We included 402 participants (mean age 57.9±3.8, 58.5% female, 52% Mexican American). Midlife cardiovascular health was assessed using the AHA Life’s Simple 7 (LS7). General cognition was measured four times over a period of 9.5 years. We used generalized estimating equations to assess the association of LS7 scores and its factors with cognitive change, overall and by ethnicity. RESULTS: Meeting intermediate or ideal physical activity goals mitigated cognitive decline, particularly in Mexican Americans, and maintaining blood glucose below 125 mg/dL was associated with slower cognitive decline among non-Hispanic Whites. Additionally, Mexican Americans with a BMI 2 showed an accelerated cognitive decline. No associations were observed between total LS7 scores and cognitive decline. DISCUSSION: Physical activity, blood glucose, and BMI have distinct contributions to cognitive change across different ethnicities.
Open AccessImpact of mid-life cardiovascular health on cognitive change in a bi-ethnic cohort
INTRODUCTION: Vascular risk factors contribute to cognitive decline and dementia; however, research across populations remains scarce. METHODS: We included 402 participants (mean age 57.9±3.8, 58.5% female, 52% Mexican American). Midlife cardiovascular health was assessed using the AHA Life’s Simple 7 (LS7). General cognition was measured four times over a period of 9.5 years. We used generalized estimating equations to assess the association of LS7 scores and its factors with cognitive change, overall and by ethnicity. RESULTS: Meeting intermediate or ideal physical activity goals mitigated cognitive decline, particularly in Mexican Americans, and maintaining blood glucose below 125 mg/dL was associated with slower cognitive decline among non-Hispanic Whites. Additionally, Mexican Americans with a BMI 2 showed an accelerated cognitive decline. No associations were observed between total LS7 scores and cognitive decline. DISCUSSION: Physical activity, blood glucose, and BMI have distinct contributions to cognitive change across different ethnicities.
- 3 April 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (7) , 940-950
Avanzando Caminos (Leading Pathways): design and procedures of the Hispanic/Latino Cancer Survivorship Study
Purpose: Avanzando Caminos (Leading Pathways): The Hispanic/Latino Cancer Survivorship Cohort Study aims to examine the influence of sociocultural, medical, stress, psychosocial, lifestyle, behavioral, and biological factors on symptom burden, health-related quality of life, and clinical outcomes among Hispanics/Latinos who have been previously treated for cancer. Methods: Avanzando Caminos is a prospective, cohort-based study of 3,000 Hispanics/Latinos who completed primary cancer treatment within the past five years that is representative of the general Hispanic/Latino population in the U.S. Participants will complete self-report measures at baseline (T1), 6 months (T2), 1 year (T3), 2 years (T4), 3 years (T5), 4 years (T6), and 5 years (T7). Blood draws to assess leukocyte gene expression, cardiometabolic markers, and genetic admixture will be collected at baseline (T1), 1 year (T3), 3 years (T5), and 5 years (T7). Medical and cancer characteristics and clinical outcomes will be extracted from the electronic medical record and/or state cancer registry at each time point. Data analysis will include general latent variable modeling and latent growth modeling. Conclusions: Avanzando Caminos will fill critical gaps in knowledge to guide future secondary and tertiary prevention efforts to mitigate cancer disparities and optimize health-related quality of life among Hispanic/Latino cancer survivors.
- 3 April 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (7) , 940-950
Avanzando Caminos (Leading Pathways): design and procedures of the Hispanic/Latino Cancer Survivorship Study
Purpose: Avanzando Caminos (Leading Pathways): The Hispanic/Latino Cancer Survivorship Cohort Study aims to examine the influence of sociocultural, medical, stress, psychosocial, lifestyle, behavioral, and biological factors on symptom burden, health-related quality of life, and clinical outcomes among Hispanics/Latinos who have been previously treated for cancer. Methods: Avanzando Caminos is a prospective, cohort-based study of 3,000 Hispanics/Latinos who completed primary cancer treatment within the past five years that is representative of the general Hispanic/Latino population in the U.S. Participants will complete self-report measures at baseline (T1), 6 months (T2), 1 year (T3), 2 years (T4), 3 years (T5), 4 years (T6), and 5 years (T7). Blood draws to assess leukocyte gene expression, cardiometabolic markers, and genetic admixture will be collected at baseline (T1), 1 year (T3), 3 years (T5), and 5 years (T7). Medical and cancer characteristics and clinical outcomes will be extracted from the electronic medical record and/or state cancer registry at each time point. Data analysis will include general latent variable modeling and latent growth modeling. Conclusions: Avanzando Caminos will fill critical gaps in knowledge to guide future secondary and tertiary prevention efforts to mitigate cancer disparities and optimize health-related quality of life among Hispanic/Latino cancer survivors.
- Open Access
A pilot study to investigate the safety and feasibility of antiretroviral therapy for Alzheimer’s disease (ART-AD)
Retrotransposons are viral-like DNA sequences that constitute approximately 41% of the human genome. Studies in Drosophila, mice, cultured cells, and human brain indicate that retrotransposons are activated in settings of tauopathy, including Alzheimer’s disease, and causally drive neurodegeneration. The anti-retroviral medication 3TC (lamivudine), a nucleoside analog reverse transcriptase inhibitor, limits retrotransposon activation and suppresses neurodegeneration in tau transgenic Drosophila, two mouse models of tauopathy, and in brain assembloids derived from patients with sporadic Alzheimer’s disease. We performed a 24-week phase 2a open-label clinical trial of 300 mg daily oral 3TC ( NCT04552795 ) in 12 participants aged 52-83 years with a diagnosis of mild cognitive impairment due to suspected Alzheimer’s disease. Primary outcomes included feasibility, blood brain barrier penetration, effects of 3TC on reverse transcriptase activity in the periphery, and safety. Secondary outcomes included changes in cognition and fluid-based biomarkers of neurodegeneration and neuroinflammation. All participants completed the six-month trial; one event of gastrointestinal bleeding due to a peptic ulcer was reported. 3TC was detected in blood and cerebrospinal fluid (CSF) of all participants, suggestive of adherence to study drug and effective brain penetration. Cognitive measures remained stable throughout the study. Glial fibrillary acidic protein (GFAP) ( P =0.03) and Flt1 ( P =0.05) were significantly reduced in CSF over the treatment period; Aβ42/40 ( P =0.009) and IL-15 ( P =0.006) were significantly elevated in plasma. While this is an open label study of small sample size, the significant decrease of some neurodegeneration- and neuroinflammation-related biomarkers in CSF, significantly elevated levels of plasma Aβ42/40, and a trending decrease of CSF NfL after six months of 3TC exposure suggest a beneficial effect on subjects with mild cognitive impairment due to suspected Alzheimer’s disease. Feasibility, safety, tolerability, and central nervous system (CNS) penetration assessments further support clinical evaluation of 3TC in a larger placebo-controlled, multi-dose clinical trial.
Open AccessA pilot study to investigate the safety and feasibility of antiretroviral therapy for Alzheimer’s disease (ART-AD)
Retrotransposons are viral-like DNA sequences that constitute approximately 41% of the human genome. Studies in Drosophila, mice, cultured cells, and human brain indicate that retrotransposons are activated in settings of tauopathy, including Alzheimer’s disease, and causally drive neurodegeneration. The anti-retroviral medication 3TC (lamivudine), a nucleoside analog reverse transcriptase inhibitor, limits retrotransposon activation and suppresses neurodegeneration in tau transgenic Drosophila, two mouse models of tauopathy, and in brain assembloids derived from patients with sporadic Alzheimer’s disease. We performed a 24-week phase 2a open-label clinical trial of 300 mg daily oral 3TC ( NCT04552795 ) in 12 participants aged 52-83 years with a diagnosis of mild cognitive impairment due to suspected Alzheimer’s disease. Primary outcomes included feasibility, blood brain barrier penetration, effects of 3TC on reverse transcriptase activity in the periphery, and safety. Secondary outcomes included changes in cognition and fluid-based biomarkers of neurodegeneration and neuroinflammation. All participants completed the six-month trial; one event of gastrointestinal bleeding due to a peptic ulcer was reported. 3TC was detected in blood and cerebrospinal fluid (CSF) of all participants, suggestive of adherence to study drug and effective brain penetration. Cognitive measures remained stable throughout the study. Glial fibrillary acidic protein (GFAP) ( P =0.03) and Flt1 ( P =0.05) were significantly reduced in CSF over the treatment period; Aβ42/40 ( P =0.009) and IL-15 ( P =0.006) were significantly elevated in plasma. While this is an open label study of small sample size, the significant decrease of some neurodegeneration- and neuroinflammation-related biomarkers in CSF, significantly elevated levels of plasma Aβ42/40, and a trending decrease of CSF NfL after six months of 3TC exposure suggest a beneficial effect on subjects with mild cognitive impairment due to suspected Alzheimer’s disease. Feasibility, safety, tolerability, and central nervous system (CNS) penetration assessments further support clinical evaluation of 3TC in a larger placebo-controlled, multi-dose clinical trial.
- 12 December 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (24) , E2571-E2584
Role of Deployment History on the Association Between Epilepsy and Traumatic Brain Injury in Post–9/11 Era US Veterans
Background and Objectives: Traumatic brain injury (TBI) is a well-established epilepsy risk factor and is common among service members. Deployment related TBI, where combat/blast may be more common, may have different outcomes than non-deployment related TBI. This work examined associations of all TBI exposures (not just combat), and epilepsy, while adjusting for comorbidities associated with epilepsy, among Veterans by deployment status. Methods: The cohort included post-9/11 Veterans with ≥ 2 years of care in both Veterans Health Administration (VHA) and Defense Health Agency (DHA) systems. We identified epilepsy using ICD-9/10-CM codes, anti-seizure medication, and service-connected disability for epilepsy. We conducted a logistic regression model with interaction terms for conditions by deployment history that adjusted for demographics and military characteristics. Results: The cohort (n=938,890) included post-9/11 Veterans of which 27,436 (2.92%) had epilepsy. Most Veterans had a history of deployment (70.64%), referred to as “deployed”. Epilepsy was more common among Veterans who were never deployed (“non-deployed”) (3.85% vs. 2.54%). Deployed Veterans were more likely to have had TBI, compared to the non-deployed (33.94% vs. 4.24%), but non-deployed Veterans with moderate/severe TBI had higher odds of epilepsy compared to deployed Veterans (aOR=2.92, 95% CI: 2.68-3.17 vs. aOR=2.01, 95% CI: 1.91-2.11). Penetrating TBI had higher odds of epilepsy among the deployed (aOR=5.33, 95% CI: 4.89-5.81), whereas the odds of epilepsy for mild TBI did not significantly differ by deployment status. Though most neurological conditions were more prevalent among non-deployed, they were often associated with higher odds of epilepsy in the deployed. Discussion: Deployment history had a significant differential impact on epilepsy predictors. As expected, penetrating TBI had a greater epilepsy impact among deployed Veterans perhaps due to combat/blast. Some epilepsy predictors (moderate/severe TBI, MS, Parkinson’s disease) had a stronger association in the non-deployed suggesting a potential healthy warrior effect in which such conditions preclude deployment. Other neurological conditions (e.g., brain tumor, Alzheimer9s disease/frontotemporal dementia) had a greater epilepsy impact in the deployed. This may be attributable to deployment related exposures (combat injury, occupational exposures). A better understanding of deployment effects is critical to provide targeted epilepsy prevention in Veterans and military service members.
- 12 December 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (24) , E2571-E2584
Role of Deployment History on the Association Between Epilepsy and Traumatic Brain Injury in Post–9/11 Era US Veterans
Background and Objectives: Traumatic brain injury (TBI) is a well-established epilepsy risk factor and is common among service members. Deployment related TBI, where combat/blast may be more common, may have different outcomes than non-deployment related TBI. This work examined associations of all TBI exposures (not just combat), and epilepsy, while adjusting for comorbidities associated with epilepsy, among Veterans by deployment status. Methods: The cohort included post-9/11 Veterans with ≥ 2 years of care in both Veterans Health Administration (VHA) and Defense Health Agency (DHA) systems. We identified epilepsy using ICD-9/10-CM codes, anti-seizure medication, and service-connected disability for epilepsy. We conducted a logistic regression model with interaction terms for conditions by deployment history that adjusted for demographics and military characteristics. Results: The cohort (n=938,890) included post-9/11 Veterans of which 27,436 (2.92%) had epilepsy. Most Veterans had a history of deployment (70.64%), referred to as “deployed”. Epilepsy was more common among Veterans who were never deployed (“non-deployed”) (3.85% vs. 2.54%). Deployed Veterans were more likely to have had TBI, compared to the non-deployed (33.94% vs. 4.24%), but non-deployed Veterans with moderate/severe TBI had higher odds of epilepsy compared to deployed Veterans (aOR=2.92, 95% CI: 2.68-3.17 vs. aOR=2.01, 95% CI: 1.91-2.11). Penetrating TBI had higher odds of epilepsy among the deployed (aOR=5.33, 95% CI: 4.89-5.81), whereas the odds of epilepsy for mild TBI did not significantly differ by deployment status. Though most neurological conditions were more prevalent among non-deployed, they were often associated with higher odds of epilepsy in the deployed. Discussion: Deployment history had a significant differential impact on epilepsy predictors. As expected, penetrating TBI had a greater epilepsy impact among deployed Veterans perhaps due to combat/blast. Some epilepsy predictors (moderate/severe TBI, MS, Parkinson’s disease) had a stronger association in the non-deployed suggesting a potential healthy warrior effect in which such conditions preclude deployment. Other neurological conditions (e.g., brain tumor, Alzheimer9s disease/frontotemporal dementia) had a greater epilepsy impact in the deployed. This may be attributable to deployment related exposures (combat injury, occupational exposures). A better understanding of deployment effects is critical to provide targeted epilepsy prevention in Veterans and military service members.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Adjusted* General Linear Model to Compare The Impact of Metformin on PSA, BMI and LDL between Race/Ethnicity Groups from Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessAdjusted* General Linear Model to Compare The Impact of Metformin on PSA, BMI and LDL between Race/Ethnicity Groups from Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Adjusted* General Linear Model to Compare The Impact of Metformin on PSA, BMI and LDL between Race/Ethnicity Groups from Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessAdjusted* General Linear Model to Compare The Impact of Metformin on PSA, BMI and LDL between Race/Ethnicity Groups from Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes
- Open Access
- 27 May 2020
- Published by Wolters Kluwer Health in Journal of Head Trauma Rehabilitation
- Vol. 36 (1) , 10-19
Health Phenotypes and Neurobehavioral Symptom Severity Among Post-9/11 Veterans With Mild Traumatic Brain Injury: A Chronic Effects of Neurotrauma Consortium Study
Objective: To evaluate whether neurobehavioral symptoms differ between groups of veterans with mild traumatic brain injury (mTBI) classified by health characteristics. Participants: A total of 71 934 post-9/11 veterans with mTBI from the Chronic Effects of Neurotrauma Consortium Epidemiology warfighter cohort. Design: Cross-sectional analysis of retrospective cohort. Main Measures: Health phenotypes identified using latent class analysis of health and function over 5 years. Symptom severity measured using Neurobehavioral Symptom Inventory; domains included vestibular, somatic, cognitive, and affective. Results: Veterans classified as moderately healthy had the lowest symptom burden while the polytrauma phenotype group had the highest. After accounting for sociodemographic and injury characteristics, polytrauma phenotype veterans had about 3 times the odds of reporting severe symptoms in each domain compared with moderately healthy veterans. Those veterans who were initially moderately healthy but whose health declined over time had about twice the odds of severe symptoms as consistently healthier Veterans. The strongest associations were in the affective domain. Compared with the moderately healthy group, veterans in other phenotypes were more likely to report symptoms substantially interfered with their daily lives (odds ratio range: 1.3-2.8). Conclusion: Symptom severity and interference varied by phenotype, including between veterans with stable and declining health. Ameliorating severe symptoms, particularly in the affective domain, could improve health trajectories following mTBI.
- 27 May 2020
- Published by Wolters Kluwer Health in Journal of Head Trauma Rehabilitation
- Vol. 36 (1) , 10-19
Open AccessHealth Phenotypes and Neurobehavioral Symptom Severity Among Post-9/11 Veterans With Mild Traumatic Brain Injury: A Chronic Effects of Neurotrauma Consortium Study
Objective: To evaluate whether neurobehavioral symptoms differ between groups of veterans with mild traumatic brain injury (mTBI) classified by health characteristics. Participants: A total of 71 934 post-9/11 veterans with mTBI from the Chronic Effects of Neurotrauma Consortium Epidemiology warfighter cohort. Design: Cross-sectional analysis of retrospective cohort. Main Measures: Health phenotypes identified using latent class analysis of health and function over 5 years. Symptom severity measured using Neurobehavioral Symptom Inventory; domains included vestibular, somatic, cognitive, and affective. Results: Veterans classified as moderately healthy had the lowest symptom burden while the polytrauma phenotype group had the highest. After accounting for sociodemographic and injury characteristics, polytrauma phenotype veterans had about 3 times the odds of reporting severe symptoms in each domain compared with moderately healthy veterans. Those veterans who were initially moderately healthy but whose health declined over time had about twice the odds of severe symptoms as consistently healthier Veterans. The strongest associations were in the affective domain. Compared with the moderately healthy group, veterans in other phenotypes were more likely to report symptoms substantially interfered with their daily lives (odds ratio range: 1.3-2.8). Conclusion: Symptom severity and interference varied by phenotype, including between veterans with stable and declining health. Ameliorating severe symptoms, particularly in the affective domain, could improve health trajectories following mTBI.
- Open Access
- 16 April 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (6) , 3206-3215
Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases
Background: We assessed racial/ethnic disparity in hepatocellular carcinoma (HCC) incidence among men with type 2 diabetes (T2D) but without chronic liver diseases (CLD), and whether metformin use modified the disparity.Methods: Study cohort: the nationwide Veterans Administration Health Care System electronic medical records among 40‐89 years old men with T2D; without CLD, cancer, cardiovascular or renal diseases previously; insulin and thiazolidinedione naive. Logistic regression analyses compared HCC incidence between race/ethnicity groups under no metformin use adjusted for covariates and inverse propensity score weights (IPSW) for race/ethnicity. The generalizability technique integrated with IPSW was incorporated to compare covariates adjusted odds ratios (aOR) of HCC associated with metformin use among race/ethnicity groups.Results: Study cohort: N = 84 433; 79.47% non‐Hispanic white (NHW), 15.5% non‐Hispanic African American (NHAA), 5.03% Hispanics; 36.76% metformin users; follow‐up 6.10 ± 2.87 years; age 67.8 ± 9.8 years, HbA1c 6.57 ± 0.98%; 0.14% HCC cases. Under no metformin use, HCC incidence was lower for NHAA vs NHW (aOR = 0.60 [0.40‐0.92]), similar between NHW and Hispanics. Metformin was associated with reduced HCC risk: aOR = 0.57 (0.40‐0.81) for NHW; aOR = 0.35 (0.25‐0.47) for NHAA; aOR = 0.31 (0.22‐0.43) for Hispanics. Metformin dose >1000 mg/d was neutral for NHW; less effective for NHAA (P = 0.02); more effective for Hispanics (P = 0.002).Conclusions: In men with T2D but without CLD nor metformin use, HCC incidence was lower for NHAA compared to NHW or Hispanics; similar between NHW and Hispanics. Metformin use reduced HCC risk and modified the race/ethnicity disparity.Impact: Metformin's heterogeneous HCC prevention effect elucidates potential interventions to modify HCC disparity in patients with T2D.
- 16 April 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (6) , 3206-3215
Open AccessMetformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases
Background: We assessed racial/ethnic disparity in hepatocellular carcinoma (HCC) incidence among men with type 2 diabetes (T2D) but without chronic liver diseases (CLD), and whether metformin use modified the disparity.Methods: Study cohort: the nationwide Veterans Administration Health Care System electronic medical records among 40‐89 years old men with T2D; without CLD, cancer, cardiovascular or renal diseases previously; insulin and thiazolidinedione naive. Logistic regression analyses compared HCC incidence between race/ethnicity groups under no metformin use adjusted for covariates and inverse propensity score weights (IPSW) for race/ethnicity. The generalizability technique integrated with IPSW was incorporated to compare covariates adjusted odds ratios (aOR) of HCC associated with metformin use among race/ethnicity groups.Results: Study cohort: N = 84 433; 79.47% non‐Hispanic white (NHW), 15.5% non‐Hispanic African American (NHAA), 5.03% Hispanics; 36.76% metformin users; follow‐up 6.10 ± 2.87 years; age 67.8 ± 9.8 years, HbA1c 6.57 ± 0.98%; 0.14% HCC cases. Under no metformin use, HCC incidence was lower for NHAA vs NHW (aOR = 0.60 [0.40‐0.92]), similar between NHW and Hispanics. Metformin was associated with reduced HCC risk: aOR = 0.57 (0.40‐0.81) for NHW; aOR = 0.35 (0.25‐0.47) for NHAA; aOR = 0.31 (0.22‐0.43) for Hispanics. Metformin dose >1000 mg/d was neutral for NHW; less effective for NHAA (P = 0.02); more effective for Hispanics (P = 0.002).Conclusions: In men with T2D but without CLD nor metformin use, HCC incidence was lower for NHAA compared to NHW or Hispanics; similar between NHW and Hispanics. Metformin use reduced HCC risk and modified the race/ethnicity disparity.Impact: Metformin's heterogeneous HCC prevention effect elucidates potential interventions to modify HCC disparity in patients with T2D.